drazizshaibani 01

Book Chapters

  1.  Shaibani A, Zahra A, AL Sultani H. Coping with Myasthenia Gravis, Authorhouse, 2021.
  2. Guest editor: Neurologic clinics: case studies in neuromuscular disorders. August 2020
  3. Video Atlas of Neuromuscular Disorders, Oxford University Press, 2018 2nd edition.
  4. Video Atlas of Neuromuscular Disorders, Oxford University Press, 2014
  5. Shaibani A, Sabbagh M, Khan B., Human crying, chapter 15 in. Adult Crying, Brunner-Routledge, 2001.
  6. Shaibani A., Harati Y., Inflammatory myopathies, chapter 16 in: Neuroimmunology for the clinician, Butterworth-Heinmann, 1997.
  7. Harati Y., Shaibani A. Inherited Autonomic Neuropathies, chapter 49 in: Primer on the Autonomic nervous System, Academic press, 1996.
  8. Shaibani A, Harati, Y. Amyloidotic Autonomic Failure, chapter 50 in: Primer on the Autonomic Nervous System, Academic press, 1996.

Journal Articles

  1. Frisaldi E, Vollert J, Al Sultani H, Benedetti F, Shaibani A. Placebo and nocebo responses in painful diabetic neuropathy: systematic review and meta-analysis. Pain. 2024 Jan 1;165(1):29-43. doi: 10.1097/j.pain.0000000000003000. Epub 2023 Aug 2. PMID: 37530658.
  2. Benedetti F, Shaibani A, Arduino C, Thoen W. Open-label nondeceptive placebo analgesia is blocked by the opioid antagonist naloxone. Pain. 2023 May 1;164(5):984-990. doi: 10.1097/j.pain.0000000000002791. Epub 2022 Sep 20. PMID: 36165878.
  3. Machado PM, McDermott MP, Blaettler T, Sundgreen C, Amato AA, Ciafaloni E, Freimer M, Gibson SB, Jones SM, Levine TD, Lloyd TE, Mozaffar T, Shaibani AI, Wicklund M, Rosholm A, Carstensen TD, Bonefeld K, Jørgensen AN, Phonekeo K, Heim AJ, Herbelin L, Barohn RJ, Hanna MG, Dimachkie MM; Arimoclomol in IBM Investigator Team of the Neuromuscular Study Group. Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 Oct;22(10):900-911. doi: 10.1016/S1474-4422(23)00275-2. PMID: 37739573.
  4. Frisaldi E, Shaibani A, Benedetti F, Pagnini F. Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review. BMJ Open. 2023 Oct 17;13(10):e077243. doi: 10.1136/bmjopen-2023-077243. PMID: 37848293; PMCID: PMC10582987.
  5. Michelson D, Chin WW, Dworkin RH, Freeman R, Herrmann DN, Mazitschek R, Pop-Busui R, Shaibani A, Vornov J, Jones M, Jarpe M, Hader B, Viera T, Hylan M, Kachmar T, Jones S. A randomized, double-blind, placebo-controlled study of histone deacetylase type 6 inhibition for the treatment of painful diabetic peripheral neuropathy. Pain Rep. 2023 Oct 26;8(6):e1114. doi: 10.1097/PR9.0000000000001114. PMID: 37899940; PMCID: PMC10611336.
  6. Benedetti F, Arduino C, Shaibani A, Thoen W. Creating Placebo Nonresponders in the Lab. J Pain. 2023 Oct 30:S1526-5900(23)00590-4. doi: 10.1016/j.jpain.2023.10.017. Epub ahead of print. PMID: 37907113.
  7. Michelson, Davida,*; Chin, William W.a; Dworkin, Robert H.b; Freeman, Royc; Herrmann, David N.b; Mazitschek, Ralphd; Pop-Busui, Rodicae; Shaibani, Azizf; Vornov, Jamesg; Jones, Melissah; Jarpe, Matthewa; Hader, Brittanyh; Viera, Theresah; Hylan, Michellea; Kachmar, Tima; Jones, Simona. A randomized, double-blind, placebo-controlled study of histone deacetylase type 6 inhibition for the treatment of painful diabetic peripheral neuropathy. PAIN Reports 8(6):p e1114, December 2023
  8. Al Sultani H, Hafeez K, Shaibani A. Diagnostic Outcome of Genetic Testing for Neuromuscular Disorders in a Tertiary Center. J Clin Neuromuscul Dis. 2022 Sep 1;24(1):1-6. doi: 10.1097/CND.0000000000000389. PMID: 36005468.
  9. Benedetti F, Amanzio M, Giovannelli F, Craigs-Brackhahn K, Arduino C, Shaibani A. Are Nocebo Effects in Adulthood Linked to Prenatal Maternal Cortisol Levels? Clin Neuropsychiatry. 2022 Oct;19(5):298-306. doi:10.36131/cnfioritieditore20220505. PMID: 36340278; PMCID: PMC9597651.
  10. Hafeez K, Kushlaf H, Al-Sultani H, Joseph AC, Zaeem Z, Siddiqi Z, Laboy S, Pulley M, Habib AA, Robbins NM, Zadeh S, Hafeez MU, Hussain Y, Melendez-Zaidi A, Kassardjian C, Johnson K, Leonhard H, Biliciler S, Patino Murillas JE, Shaibani AI. Patient preference for virtual versus in-person visits in neuromuscular clinical practice. Muscle Nerve. 2022 Aug;66(2):142-147. doi: 10.1002/mus.27641. Epub 2022 Jun 3. PMID: 35596667; PMCID: PMC9540760.
  11. Kim Y, Li X, Huang Y, Kim M, Shaibani A, Sheikh K, Zhang GQ, Nguyen TP. COVID-19 Outcomes in Myasthenia Gravis Patients: Analysis From Electronic Health Records in the United States. Front Neurol. 2022 Mar 28;13:802559. doi: 10.3389/fneur.2022.802559. PMID: 35418937; PMCID: PMC8996116.
  12. Frisaldi E, Shaibani A, Trucco M, Milano E, Benedetti F. What is the role of placebo in neurotherapeutics? Expert Rev Neurother. 2022 Jan;22(1):15-25. doi: 10.1080/14737175.2022.2012156. Epub 2021 Dec 13. PMID: 34845956.
  13. Shaibani A, Khan S, Shinawi M. Autosomal Dominant ANO5-Related Disorder Associated With Myopathy and Gnathodiaphyseal Dysplasia. Neurol Genet. 2021 Jul 16;7(4):e612. doi: 10.1212/NXG.0000000000000612. PMID: 34291158; PMCID: PMC8290902.
  14. Cudkowicz M, Genge A, Maragakis N, Petri S, van den Berg L, Aho VV, Sarapohja T, Kuoppamäki M, Garratt C, Al-Chalabi A; REFALS investigators. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2021 Oct;20(10):821-831. doi: 10.1016/S1474-4422(21)00242-8. PMID: 34536404.
  15. Benedetti F, Amanzio M, Giovannelli F, Craigs-Brackhahn K, Shaibani A. Hypothalamic-Pituitary-Adrenal Activity in Adverse Events Reporting After Placebo Administration. Clin Pharmacol Ther. 2021 Nov;110(5):1349-1357. doi: 10.1002/cpt.2388. Epub 2021 Aug 23. PMID: 34365636.
  16. Wencel M, Shaibani A, Goyal NA, Dimachkie MM, Trivedi J, Johnson NE, Gutmann L, Wicklund MP, Bandyopadhay S, Genge AL, Freimer ML, Goyal N, Pestronk A, Florence J, Karam C, Ralph JW, Rasheed Z, Hays M, Hopkins S, Mozaffar T. Investigating Late-Onset Pompe Prevalence in Neuromuscular Medicine Academic Practices: The IPaNeMA Study. Neurol Genet. 2021 Oct 18;7(6):e623. doi: 10.1212/NXG.0000000000000623. PMID: 36299500; PMCID: PMC9595038.
  17. Benedetti F, Frisaldi E, Barbiani D, Camerone E, Shaibani A (2020) Nocebo and the to the generation of pain. J Neural Transm, 127: 687-696. 
  18. Frisaldi E, Shaibani A, Benedetti F (2020) Understanding placebo and nocebo effects. Swiss Med Wkly, 150: w20340. 
  19. Frisaldi E, Shaibani A, Benedetti F (2021) Placebo/nocebo: a two-sided coin in the clinician’s hands. In: Lynch ME, Craig KD, Peng PWH (Eds), Clinical Pain Management: A Practical Guide, 2nd Edition. Oxford: Blackwell. 
  20. Frisaldi E, Shaibani A, Benedetti F (2021) Placebo and nocebo effects in clinical trials and clinical practice. In: Benzon HT et al. (Eds), Practical Management of Pain, 6th edition. Elsevier. 
  21. Frisaldi E, Shaibani A, Trucco M, Milano E, Benedetti F (2022) What is the role of placebo in neurotherapeutics? Exp Rev Neurother, in press. 
  22. Frisaldi E, Shaibani A, Benedetti F. Placebo Effect. In: Encyclopedia of Behavioral Neuroscience, 2nd Edition. Elsevier; 2022:731-738. doi:10.1016/B978-0-12-809324-5.24091-1
  23. Al sultani, H., K. Hafeez, M. Hafeez, and A. Shaibani. “Physicians Preferences of Virtual Versus In-Person Visits in Neuromuscular Clinical Practice: Telemedicine Preference of Neuromuscular Practitioners”. RRNMF Neuromuscular Journal, vol. 2, no. 4, Sept. 2021, https://journals.ku.edu/rrnmf/article/view/15456.
  24. Benedetti F, Frisaldi E, Shaibani A. Thirty Years of Neuroscientific Investigation of Placebo and Nocebo: The Interesting, the Good, and the Bad [published online ahead of print, 2021 Aug 30]. Annu Rev Pharmacol Toxicol. 2021;10.1146/annurev-pharmtox-052120-104536. doi:10.1146/annurev-pharmtox-052120-104536
  25. Benedetti F, Amanzio M, Giovannelli F, Craigs-Brackhahn K, Shaibani A. Hypothalamic-Pituitary-Adrenal Activity in Adverse Events Reporting after Placebo Administration [published online ahead of print, 2021 Aug 8]. Clin Pharmacol Ther. 2021;10.1002/cpt.2388. doi:10.1002/cpt.2388
  26. Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. PMID: 33597289; PMCID: PMC8032371.
  27. Shaibani A, Khan S, Shinawi M. Autosomal Dominant ANO5-Related Disorder Associated With Myopathy and Gnathodiaphyseal Dysplasia. Neurol Genet. 2021;7(4):e612. Published 2021 Jul 16. doi:10.1212/NXG.0000000000000612
  28. Sung A, Moretti P, Shaibani A. Adult-Onset Spinal Muscular Atrophy due to Mutations in the VRK1 Gene. Neurol Genet. 2021;7(4):e599. Published 2021 Jun 22. doi:10.1212/NXG.0000000000000599
  29. Lopez MA, Bontiff S, Adeyeye M, Shaibani AI, Alexander MS, Wynd S, Boriek AM. Mechanics of dystrophin deficient skeletal muscles in very young mice and effects of age. Am J Physiol Cell Physiol. 2021 Aug 1;321(2):C230-C246. doi: 10.1152/ajpcell.00155.2019. Epub 2021 May 12. PMID: 33979214; PMCID: PMC8424675.
  30. Kessler JA, Shaibani A, Sang CN, et al. Gene therapy for diabetic peripheral neuropathy: A randomized, placebo-controlled phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021;14(3):1176-1184. doi:10.1111/cts.12977
  31. Benedetti F, Frisaldi E, Barbiani D, Camerone E, Shaibani A. Nocebo and the contribution of psychosocial factors to the generation of pain. J Neural Transm (Vienna). 2020 Apr;127(4):687-696. doi: 10.1007/s00702-019-02104-x. Epub 2019 Nov 22. PMID: 31758266.
  32. Shaibani A, Al Sultani H. Refractory Chronic Immune-mediated Demyelinating Polyneuropathy. Neurol Clin. 2020 Aug;38(3):591-605. doi: 10.1016/j.ncl.2020.03.006. Epub 2020 Jun 11. PMID: 32703471.
  33. Frisaldi E, Shaibani A, Benedetti F. Understanding the mechanisms of placebo and nocebo effects. Swiss Med Wkly. 2020 Sep 1;150:w20340. doi: 10.4414/smw.2020.20340. PMID: 32920787.
  34. Lee I, Kuo HC, Aban IB, Cutter GR, McPherson T, Kaminski HJ, Sussman J, Ströbel P, Oger J, Cea G, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJG, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Minisman G, Sonett JR, Wolfe GI; MGTX study group. Minimal manifestation status and prednisone withdrawal in the MGTX trial. Neurology. 2020 Aug 11;95(6):e755-e766. doi: 10.1212/WNL.0000000000010031. Epub 2020 Jul 1. PMID: 32611638; PMCID: PMC7455358.
  35. Patient Preference in Virtual Versus In-Person Visits in Neuromuscular Clinical Practice. H. Al Sultani, K. Hafeez, A .Shaibani, A . Habib, H. Kushlaf , K. Johnson, N. Robbins, Z Siddiqi. RRNMF Neuromuscular Journal. 2020/09 DOI: https://doi.org/10.17161/rrnmf.v1i4.
  36. Diagnostic  Outcome  Of  Genetic  Testing  on  Neuromuscular  Disorders  in  a  Tertiary Center. H. Al Sultani, K. Naeem, A . Mendez-Zaidi, A . Shaibani. RRNMF Neuromuscular Journal. 2020/09 DOI: https://doi.org/10.17161/rrnmf.v1i4
  37. Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, Aoki M, Machado PM, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Katsuno M, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Auberson LZ, Wu M, de Vera A, Papanicolaou DA, Amato AA; RESILIENT Study Group. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019 Sep;18(9):834-844. doi: 10.1016/S1474-4422(19)30200-5. PMID: 31397289.
  38. Benedetti F, Shaibani A. Nocebo effects: more investigation is needed. Expert Opin Drug Saf. 2018 Jun;17(6):541-543. doi: 10.1080/14740338.2018.1474199. Epub 2018 May 16. PMID: 29768057.
  39. Benedetti F, Frisaldi E, Shaibani A. Placebo effects: the need for a new perspective and conceptualization. Expert Rev Clin Pharmacol. 2018 Jun;11(6):543-544. doi: 10.1080/17512433.2018.1475228. Epub 2018 May 21. PMID: 29745259.
  40. Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI.
    Gwathmey KG, Sadjadi R, Horton WB, Conaway MR, Barnett-Tapia C, Bril V, Russell JW, Shaibani A, Mauermann ML, Hehir MK, Kolb N, Guptill J, Hobson-Webb L, Gable K, Raja S, Silvestri N, Wolfe GI, Smith AG, Malik R, Traub R, Joshi A, Elliott MP, Jones S, Burns TM.Neurology. 2018 Jun 5;90(23):e2034-e2041.
  41. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25. PMID: 30692052; PMCID: PMC6774753.
  42. Frisaldi E, Shaibani A, Vollert J, Ferrero B, Carrino R, Ibraheem HD, Vase L, Benedetti F. The placebo response in myasthenia gravis assessed by quantitative myasthenia gravis score: A meta-analysis. Muscle Nerve. 2019 Jun;59(6):671-678. doi: 10.1002/mus.26469. Epub 2019 Apr 2. PMID: 30883809.
  43. Benedetti F, Firsaldi E, Shaibani A (2018) ” Placebo effects:  The need for a new perspective and coceptualization ”  Exp Rev Clin   Pharmacol
  44. Frisaldi E, Shaibani A, Benedetti F. Placebo responders and nonresponders: what’s new? Pain Manag. 2018 Nov 1;8(6):405-408. doi: 10.2217/pmt-2018-0054. PMID: 30873895.
  45. Komal FNU, Moretti PM, Shaibani AI. Deoxyguanosine kinase mutation producing juvenile-onset mitochondrial myopathy. Neurol Genet. 2018 Sep 19;4(5):e269. doi: 10.1212/NXG.0000000000000269. PMID: 30283818; PMCID: PMC6167180.
  46. Sung AR, Moretti P, Shaibani A. Case of late-onset Sandhoff disease due to a novel mutation in the HEXB gene. Neurol Genet. 2018 Jul 27;4(4):e260. doi: 10.1212/NXG.0000000000000260. PMID: 30065954; PMCID: PMC6066361.
  47. Gwathmey KG, Sadjadi R, Horton WB, Conaway MR, Barnett-Tapia C, Bril V, Russell JW, Shaibani A, Mauermann ML, Hehir MK, Kolb N, Guptill J, Hobson-Webb L, Gable K, Raja S, Silvestri N, Wolfe GI, Smith AG, Malik R, Traub R, Joshi A, Elliott MP, Jones S, Burns TM. Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy: CAPPRI. Neurology. 2018 Jun 5;90(23):e2034-e2041. doi: 10.1212/WNL.0000000000005643. Epub 2018 May 4. PMID: 29728528; PMCID: PMC5993178.
  48. Benedetti F, Shaibani A (2018) “Nocebo effects: more investigation is needed”   Exp Opin Drug Safety
  49. Shaibani A, Frisaldi E, Benedetti F. Placebo response in pain, fatigue, and performance: Possible implications for neuromuscular disorders. Muscle Nerve. 2017 Sep;56(3):358-367. doi: 10.1002/mus.25635. Epub 2017 May 30. PMID: 28249354.
  50. Bainbridge J, De Backer M, Eckhardt K, Tennigkeit F, Bongardt S, Sen D, Werhahn KJ, Shaibani A, Faught E. Safety and tolerability of lacosamide monotherapy in the elderly: A subgroup analysis from lacosamide trials in diabetic neuropathic pain. Epilepsia Open. 2017 Sep 11;2(4):415-423. doi: 10.1002/epi4.12079. PMID: 29588972; PMCID: PMC5862116.
  51. Frisaldi E, Shaibani A, Benedetti F. Why We should Assess Patients’ Expectations in Clinical Trials. Pain Ther. 2017 Jun;6(1):107-110. doi: 10.1007/s40122-017-0071-8. Epub 2017 May 5. PMID: 28477082; PMCID: PMC5447548.
  52. Khalid U, Massumi A, Shaibani A. Swallowing-induced Supraventricular Tachyarrhythmia. Rev Cardiovasc Med. 2017;18(1):53-58. doi: 10.3909/ricm0863. PMID: 28509894.
  53. Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group. Randomized Trial of Thymectomy in Myasthenia Gravis. N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text]. PMID: 27509100; PMCID: PMC5189669.
  54. Randomized Trial of Thymectomy in Myasthenia Gravis
    N Engl J Med 2016; 375:511-522August 11, 2016DOI: 10.1056/NEJMoa1602489
    Gil I. Wolfe, M.D., Henry J. Kaminski, M.D., Inmaculada B. Aban, Ph.D., Greg Minisman, M.A., Hui-Chien Kuo, M.S., Alexander Marx, M.D., Philipp Ströbel, M.D., Claudio Mazia, M.D., Joel Oger, M.D., J. Gabriel Cea, M.D., Jeannine M. Heckmann, M.B., Ch.B., Ph.D., Amelia Evoli, M.D., Wilfred Nix, M.D., Emma Ciafaloni, M.D., Giovanni Antonini, M.D., Rawiphan Witoonpanich, M.D., John O. King, M.D., Said R. Beydoun, M.D., Colin H. Chalk, M.D., Alexandru C. Barboi, M.D., Anthony A. Amato, M.D., Aziz I. Shaibani, M.D., Bashar Katirji, M.D., Bryan R.F. Lecky, M.D., Camilla Buckley, M.D., Angela Vincent, M.B., B.S., Elza Dias-Tosta, M.D., Ph.D., Hiroaki Yoshikawa, M.D., Ph.D., Márcia Waddington-Cruz, M.D., Ph.D., Michael T. Pulley, M.D., Ph.D., Michael H. Rivner, M.D., Anna Kostera-Pruszczyk, M.D., Robert M. Pascuzzi, M.D., Carlayne E. Jackson, M.D., Guillermo S. Garcia Ramos, M.D., Jan J.G.M. Verschuuren, M.D., Janice M. Massey, M.D., John T. Kissel, M.D., Lineu C. Werneck, M.D., Ph.D., Michael Benatar, M.D., Ph.D., Richard J. Barohn, M.D., Rup Tandan, M.D., Tahseen Mozaffar, M.D., Robin Conwit, M.D., Joanne Odenkirchen, M.P.H., Joshua R. Sonett, M.D., Alfred Jaretzki, III, M.D., John Newsom-Davis, M.D., and Gary R. Cutter, Ph.D., for the MGTX Study Group*
  55. A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.
    Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF Jr, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ; Methotrexate in MG Investigators of the Muscle Study Group.
    Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15.
  56. Fulminant spinal cord compression caused by postradiation inflammatory pseudotumor with rapid response to steroids: case report.
    Verla T, Thomas JG, Thomazy V, Fuller GN, Shaibani A, Omeis I.
    J Neurosurg Spine. 2016 May 27:1-5. [Epub ahead of print]
  57. Shaibani A. Distal Myopathies: Case Studies. Neurol Clin. 2016 Aug;34(3):547-64. doi: 10.1016/j.ncl.2016.04.014. PMID: 27445241.
  58. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.
    Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI.
    Muscle Nerve. 2016 Feb;53(2):165-8. doi: 10.1002/mus.25009. Epub 2015 Dec 21.
  59. Gang Q, Bettencourt C, Machado PM, Brady S, Holton JL, Pittman AM, Hughes D, Healy E, Parton M, Hilton-Jones D, Shieh PB, Needham M, Liang C, Zanoteli E, de Camargo LV, De Paepe B, De Bleecker J, Shaibani A, Ripolone M, Violano R, Moggio M, Barohn RJ, Dimachkie MM, Mora M, Mantegazza R, Zanotti S, Singleton AB, Hanna MG, Houlden H; Muscle Study Group and The International IBM Genetics Consortium. Rare variants in SQSTM1 and VCP genes and risk of sporadic inclusion body myositis. Neurobiol Aging. 2016 Nov;47:218.e1-218.e9. doi: 10.1016/j.neurobiolaging.2016.07.024. Epub 2016 Aug 8. PMID: 27594680; PMCID: PMC5082791.
  60. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
    Polydefkis M, Arezzo J, Nash M, Bril V, Shaibani A, Gordon RJ, Bradshaw KL, Junor RW; Ranirestat Study Group.
    J Peripher Nerv Syst. 2015 Dec;20(4):363-71. doi: 10.1111/jns.12138.
  61. Polydefkis et al: LACK OF DIABETIC NEUROPATHY PROGRESSION ON PLACEBO: IMPACTON A RANDOMIZED STUDY: J Peripher Nerv Syst. 2015 Dec;20(4):363-71.. PMID:26313450
  62. Double-blind, placebo-controlled study of HGF gene therapy in diabetic neuropathy.
    Kessler JA, Smith AG, Cha BS, Choi SH, Wymer J, Shaibani A, Ajroud-Driss S, Vinik A; VM202 DPN-II Study Group.
    Ann Clin Transl Neurol. 2015 May;2(5):465-78. doi: 10.1002/acn3.186. Epub 2015 Mar 5.
  63. The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis.
    Gang Q, Bettencourt C, Machado PM, Fox Z, Brady S, Healy E, Parton M, Holton JL, Hilton-Jones D, Shieh PB, Zanoteli E, De Paepe B, De Bleecker J, Shaibani A, Ripolone M, Violano R, Moggio M, Barohn RJ, Dimachkie MM, Mora M, Mantegazza R, Zanotti S, Hanna MG, Houlden H; Muscle Study Group and the International IBM Genetics Consortium.
    Neurobiol Aging. 2015 Apr;36(4):1766.e1-3. doi: 10.1016/j.neurobiolaging.2014.12.039. Epub 2015 Jan 14.
  64. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study.
    Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D; DS5565-A-U201 US Phase II Study Investigators.
    Diabetes Care. 2014 Dec;37(12):3253-61. doi: 10.2337/dc14-1044. Epub 2014 Sep 17.Collaborators
    Akright L, Andersen JL, Aroda V, Ratner R, Aronoff S, Arslanian A, Bauch T, Biton V, Brownstone P, Bruce T, Chaykin L, Christensen J, Chuck L, Cohen L, Curtis CT, Degarmo R, Denker P,Ellenbogen A, Ervin J, Fried D, Gerard G, Gibson M, Golden G, Haase G, Hernandez M, Hudson J, Huffman D, Huling R, Hull R, Hurley S, Kesten J, Kivitz A, Klymiuk A, Kudrow D, Kumar V, Liss J, Mariano H, Martin P, Mayfield R, McAllister P, McKenzie W, Miller S, Montano C, Mosley J,Obiekwe M, Omidvar O, Pellegrino R, Penc S, Perley M, Posadas M, Goldberg C, Raikhel M,Recknor C, Reed L, Reichman A, Rendell M, Reyes H, Richter R, Roberts J, Rosenblit P,Rosenstock J, Rovner S, Samson MB, Sauter M, Shaibani A, Singer R, Sligh T, Smith T, Strout D, Surprenant M, Sussman A, Taber L, Tark M, Trevino M, Unger JR, Vinik A, Wilks K, Wombolt D, Young D, Zemel L, Zieve F, Zimmerman T.
  65. Diagnostic outcome of muscle biopsy.
    Shaibani A, Jabari D, Jabbour M, Arif C, Lee M, Rahbar MH.
    Muscle Nerve. 2015 May;51(5):662-8. doi: 10.1002/mus.24447. Epub 2015 Mar 31.
  66. Autosomal Recessive Posterior Column Ataxia with Retinitis Pigmentosa Caused by Novel Mutations in the FLVCR1 gene. Shaibani A, et al. IJ Neurosci 2014 17.
  67. Jasim S, Shaibani A. Nonsarcoid granulomatous myopathy: two cases and a review of literature. Int J Neurosci. 2013 Jul;123(7):516-20. doi: 10.3109/00207454.2013.765871. Epub 2013 Feb 19. PMID: 23311755.
  68. Nonsarcoid granulomatous myopathy. Jasim S., Shaibani A. Int J Neurosci. 2013 Jul;123(7):516-20
  69. Ann N Y Acad Sci. 2012 Dec;1275:23-8. doi: 10.1111/j.1749-6632.2012.06804.x. Phase II trial of methotrexate in myasthenia gravis. Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ; Muscle Study Group.
  70. POLG mutation in a patient with cataracts, early-onset distal muscle weakness and atrophy, ovarian dysgenesis and 3-methylglutaconic aciduria. Bekheirnia MR, Zhang W, Eble T, Willis A, Shaibani A, Wong LJ, Scaglia F, Dhar SU.Gene. 2012 May 10;499(1):209-12. Epub 2012 Mar 3.
  71. Aziz I. Shaibani MD1,*, Laura E. Pope PhD2, Ronald Thisted PhD3, Adrian Hepner MD2, Efficacy and Safety of Dextromethorphan/Quinidine at Two Dosage Levels for Diabetic Neuropathic Pain: A Double-Blind, Placebo-Controlled, Multicenter Study. Volume 13, Issue 2, pages 243–254, February 2012
  72. Bedlack RS, Genge A, Amato AA, Shaibani A, Jackson CE, Kissel JT, Wall C, King WM, Cupler E, Lou JS, Ensrud E, Tan E, Goldstein JM, Katz J, Dimachkie MM, Barohn RJ, Mozaffar T. Correspondence regarding: TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 2010:69;918-29. J Neuropathol Exp Neurol. 2011 Jan;70(1):96-7; author reply 98-100. doi: 10.1097/NEN.0b013e318204782b. PMID: 21173608.
  73. Homam Ibrahim, MD, Mazen M. Dimachkie, MD, FAAN,and Aziz Shaibani, MD, FACP, FAAN; A Review: The Use of Rituximab in Neuromuscular Diseases; Journal of Clinical Neuromuscular Disease (Dec 2010) Volume 12, Number 2
  74. Srikanth Muppidi, MD, David S. Saperstein, MD, Aziz Shaibani, MD, Sharon P. Nations, MD, Steven Vernino, MD, PhD, and Gil I. Wolfe, MD; Isolated Neck Extensor Myopathy: Is it Responsive to Immunotherapy?; Journal of Clinical Neuromuscular Disease (Sep 2010) Volume 12, Number 1
  75. H Mendez-Figueroa, OA Shchelochkov, A Shaibani, K Aagaard-Tillery and MS Shinawi; Clinical and biochemical improvement of very long-chain acyl-CoA dehydrogenase deficiency in pregnancy; Journal of Perinatology (2010) 30, 558–562
  76. Nicola Brunetti-Pierri, Aziz Shaibani, Shulin Zhang, Lee-Jun Wong, Marwan Shinawi; Progressive Myopathy With Multiple Symmetric Lipomatosis; ARCH NEUROL/VOL 66 (NO. 12), DEC 2009, PP 1576-1577
  77. Aziz Shaibani, MD, et al. Mitochondrial Neurogastrointestinal Encephalopathy Due to Mutations in RRM2B. Arch Neuro, vol 66(no 8), Aug 2009.
  78. Aziz Shaibani, MD, Duaa Jabari, MD. Treatment of Autonomic Neuropathy. Medlink Neurology, an online resource for neurology. Aug 2009.
  79. Aziz Shaibani, MD, Duaa jabari, MD. Asymptomatic HyperCKemia, Medlink Neurology. Medlink Neurology, October, 2009
  80. Shchelochkow O, Wong L N, Shaibani A, Shinawi M. Atypical presentation of VLCAD deficiency associated with a novel ACADLV splicing mutation. Muscle & Nerve 39:374-389, 2009.
  81. Aziz Shaibani, MD,Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial.
    Shaibani A, Fares S, Selam JL, Arslanian A, Simpson J, Sen D, Bongardt S.
    J Pain. 2009 Aug;10(8):818-28. Epub 2009 May 5.
  82. Shchelochkov O, Wong LJ, Shaibani A, Shinawi M. Atypical presentation of VLCAD deficiency associated with a novel ACADVL splicing mutation. Muscle Nerve. 2009 Mar;39(3):374-82. doi: 10.1002/mus.21157. PMID: 19208414.
  83. Aziz Shaibani, MD, et al, Long-term oral lacosamide in painful diabetic neuropathy: A two-year open-label extension trial, European Journal of Pain, 10 July 2008.
  84. Pankaj Sajita, Aziz Shaibani. Diabetic Amyotrophy. Medlink Neurology. Louis Weimer. 2007.
  85. Ahmad Beydoun, Margaret Hopwood, Ying Wan, Aziz Shaibani, Jennifer Mazzola. Oxcarbazepine in Painful Diabetic Neuropathy: Results of a Dose-Ranging Study. Scandinavian Neurologica 2006, 113: 395-404, 2006.
  86. Zeyu Xiong, Aziz Shaibani, Yiping Li, Sheng Zhang, Bernard Ng, Yu Yang, Hong Wang, Xiao-Feng Yang. Alternative Splicing Factor ASF/SF2 is Downregulated in Inflamed Muscle. Xiong Z, Shaibani A, Li Y-P, Yan Y, Zhang S, Yang Y, Yang F, Wang H, Yang X-F. The expression of alternative splicing factor ASF/SF2 is downregulated in inflamed muscle. J Clin Pathol 59: 855-861, 2006.
  87. Richard Rauk, MD, Aziz Shaibani, MD, Victor Biton, MD, Lusiana Loman, MD, Jeff Simpson, PhD, Brigette Koch, PhD. Lacosamide in painful diabetic peripheral neuropathy: a phase II double-blind placebo-controlled trial. Clinical Journal of pain. 23(2):150-158, 2007
  88. Rauck RL, Shaibani A, Biton V, Simpson J, Koch B. Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain. 2007 Feb;23(2):150-8. doi: 10.1097/01.ajp.0000210957.39621.b2. PMID: 17237664.
  89. Shaibani A, When to suspect Amyotrophy in Diabetes patients: Expert opinion, Practical neurology, January 2005, 76-77
  90. Invited book review, Textbook of Diabetic Neuropathy, Gries FA. et all, The Lancet Neurology Vol.2, Oct. 2003, GUS.
  91. Shaibani A, Sabbagh Marwan. Pseudoneurological syndromes: recognition and diagnosis. American Family Physician; 57:2485-92, 1998.
  92. Harati Y., Gooch C., Shaibani A. Moving toes and myoclonus associated with hereditary neuropathy with liability to pressure palsy (HNPP). Muscle & Nerve; 20:881-83, 1997.
  93. Athni S, Shaibani A, Ashizawa T. Anticipation and myotonic dystrophy: Diagnostic and prognostic implications. Resident and Staff Physician 42:57-63, 1996.
  94. Safi H, Iliopoulos DC, Gopinath SP, Hess KR, Asimacopoulos PJ, Bartoli S, Raskin SA, Shaibani A, Leveque M, and Yawn DH. Retrograde cerebral perfusion during profound hypothermia and circulatory arrest in pigs. The Annals of Thoracic Surgery; 59:1107-12, 1995.
  95. Shaibani A, et al. Laughter and Crying in neurologic disorders. Journal of Neuropsychiatry, Neuropsychology and Behavioral Neurology, 7:243-250, 1994.

Abstracts & Posters

  1. The placebo effect in Myasthenia Gravis: a meta analysis.  E. Firsaldi, A Shaibani, et al.  ICNMD 2018, July 6-10 2018 Austria
  2. Diagnostic outcome of muscle biopsy in Asymptomatic HyperCKemia (AN) 2015 Abbual Meeting. September 27-29, 2015, A. Shaibani, Ali Habeeb, Duaa Jabari
  3. NMO and MG: are they related?  5th Annual UC Irvine Neuromuscular Colloquium to be May 29th, 2015. Aziz Shaibani, Ali Habeeb
  4. Diagnostic outcome of muscle biopsy in patients with symptomatic hyperCKemia. Ali Habeeb, Duaa Jabari, AzizShaibani ANA meeting 2015, Chicago
  5. Congenital myasthenic syndrome.  Review. Poster. MSG. 2016
  6. Phase II Trial of Methotrexate in Myathenia Gravis, platform presentation, American Academy of Neurology 66th Annual Meeting, April 26 to May 3, 2014
  7. Familial ataxia. P-27. H.Alazzawi, N. Hussin, A. Shaibani. Clinical neuromuscular disease. Volume 15, number 3, march 2014
  8. Family with sensory ataxia and visual impairment. A.Shaibani, et al. P-26 Clinical neuromuscular disease. Volume 15, number 3, march 2014.
  9. S-10 Predictors of Muscle Biopsy Outcome In A Tertiary Neuromuscular Center, 35th Annual Carrell-Krusen Neuromuscular Symposium, Journal of CLINICAL NEUROMUSCULAR DISEASE, Volume 14, Number 3, March 2013.
  10. P-19 Incidence and Risk Factors Of Side Effects Of Outpatient Plasmapheresis In Patients With Neuromuscular Diseases, 35th Annual Carrell-Krusen Neuromuscular Symposium, Journal of CLINICAL NEUROMUSCULAR DISEASE, Volume 14, Number 3, March 2013.
  11. B-11 Cardiomyopathy Case, 35th Annual Carrell-Krusen Neuromuscular Symposium, Journal of CLINICAL NEUROMUSCULAR DISEASE, Volume 14, Number 3, March 2013.
  12. Swallowing Induced Atrial Tachyarrythmias: A Case Report And Review Of 43 Cases — Umair Khalid, Farshad Raissi Shabari, Ali Massumi, Aziz Shaibani. 2013 Annual Southeast Acp Associates Program, March 23, 2013, Houston, Texas.
  13. Incidence and risk factors of side effects of outpatient plasmapheresis in patients with neuromuscular diseases. Nawar Hussin, Jagar Jassim, Aziz Shaibani. The 35th Annula Carrell-Krusen Neuromuscular Symposium. February 14-15, 2013. Dallas, Texas
  14. Cardiomyopathy case.  Erica Zakhem, Aziz Shaibani. The 35th Annula Carrell-Krusen Neuromuscular Symposium. February 14-15, 2013. Dallas, Texas
  15. Predictors of muscle biopsy outcome in a tertiary neuromuscular center. Chia Arif, Jagar Jassim, Aziz Shaibani. The 35th Annula Carrell-Krusen Neuromuscular Symposium. February 14-15, 2013. Dallas, Texas
  16. Predictors of Muscle Biopsy Outcomes in a Tertiary Neuromuscular Center. Chia Arif, Houston, TX, Jagar Jasem, Aziz Shaibani. AAN 65th annual meeting, March 16-23, 2013. San Diego, USA
  17. The Incidence of Adverse Effects Following Plasmapheresis Compared to IVIG in Patients with Neuromuscular Diseases Jagar Jasem, Nawar Hassn, Aziz Shaibani. March 16-23, 2013. San Diego, USA
  18. EPIDEMIOLOGY OF AMYOTROPHIC LATERAL SCLEROSIS IN TEXAS, A. M. Paker, K. Sheikh*, A. Shaibani* (Galveston, TX; Houston, TX) The AANED 59th annual meeting, October 3-6, 2012; Orlando Florida
  19. TREATMENT RESPONSE OF SUSPECTED CIDP PATIENTS NOT MEETING STANDARD DIAGNOSTIC CRITERIA; David S. Saperstein (1, 2), Todd D. Levine (1, 2), Kenneth G. Gorson (3), Gil I. Wolfe (4), Sri Muppidi (4), Aziz Shaibani (5), Michael K. Hehir (6), Ted Burns (6), Khema R. Sharma (7), Mamatha Pasnoor (8), Mazen Dimachkie (8), April L. McVey (8), and Richard J. Barohn (8) J Peripheral Nervous Syst 2011;16(Suppl 3):S124.
  20. D. Jabari, A. Shaibani, Houston, TX. Chronic Distal Weakness. Clinical Neuromuscular Disease: March 2011-Volume 12- Issue 3- PP 11
  21. C. Arif, A. Shaibani, Houston, TX. Muscule Twitching and Loss of Balance. Clinical Neuromuscular Disease: March 2011-Volume 12- Issue 3- PP 23
  22. Y. Hannawi, A. Shaibani, Houston, TX. Recurrent Respiratory Failure. Clinical Neuromuscular Disease: March 2011-Volume 12- Issue 3- PP 14-15
  23. A. Shaibani, N. Hussin, Houston TX. Familial Hoarseness and Distal Weakness. Clinical Neuromuscular Disease: March 2011-Volume 12- Issue 3- PP 16
  24. S. Majmudar, A. Shaibani, Houston, TX. Chronic Proximal and Disatal Weakness. Clinical Neuromuscular Disease: March 2011-Volume 12- Issue 3- PP 14
  25. V. Hoyos, A. Shaibani, Houston, TX. Respiratory Failure Triggered by car Accident. Clinical Neuromuscular Disease: March 2011-Volume 12- Issue 3- PP 11
  26. D. Jabari, A. Shaibani, Houston, TX. Chronic Distal Weakness. Clinical Neuromuscular Disease: March 2011-Volume 12- Issue 3- PP 11
  27. Journal of Clinical Neuromuscular Disease: March 2010 – Volume 11 – Issue 3 – pp 167-185.
  28. A. Shaibani, C. Arif, Houston, TX. Inherited fatty acid oxidation disorder resolves during pregnancy
  29. Journal of Clinical Neuromuscular Disease: March 2010 – Volume 11 – Issue 3 – pp 167-185.
  30. H. Ibraheim, C. Arif, A. Shaibani, Houston, TX. Severe muscle cramps and restlessness
  31. Journal of Clinical Neuromuscular Disease: March 2010 – Volume 11 – Issue 3 – pp 167-185.
  32. D. Jabari, C. Arif, A. Shaibani, Houston, TX. Progressive unilateral spastic hemiplegia
  33. Y. Hannawi, A. Shaibani, C. Arif, Houston, TX. Five cases of diplopia and negative brain Magnetic resonance imaging (MRIs). Journal of Clinical Neuromuscular Disease: March 2010 – Volume 11 – Issue 3 – pp 167-185.
  34. N. Brunetti-Pierri, A. Shaibani, L.-J. Wong, M. Shinawi, Houston, TX. A 56-year-old patient presenting with progressive myopathy. Journal of Clinical Neuromuscular Disease, volume 10, number 3, March 2009.
  35. O. Shchelochkov, A. Shaibani, L.-J. Wong, M. Shinawi, Houston, TX. A 42-year-old woman with generalized muscle weakness and ophthalmoplegia. Journal of Clinical Neuromuscular Disease, volume 10, number 3, March 2009
  36. M. Ummat, P. Satija, Z. Cheema, A. Shaibani, Houston, TX. Is this a case of refractory CIDP? Journal of Clinical Neuromuscular Disease, volume 10, number 3, March 2009.
  37. P. Satija, M. Ummat, H. Derman, A. Shaibani, Houston, TX. An unusual case of proximal muscle weakness with bilateral winging of the scapula. Journal of Clinical Neuromuscular Disease, volume 10, number 3, March 2009.
  38. Z. Cheema, P. Wisdom, T. Khan, S. Zubair, A. Shaibani, Oklahoma City, OK.A patient with relapsing weakness, dizziness and weight loss. Journal of Clinical Neuromuscular Disease, volume 10, number 3, March 2009
  39. Aziz Shaibani, MD The American Academy of Pain Management, 19th Annual Clinical Meeting, Nashville, Sept 8-11, 2008 Evaluation of lacosamide in diabetic neuropathic pain trials 
  40. Aziz Shaibani, MDThe American academy of pain management, 19th annual clinical meeting, Nashville, Sept 8-11, 2008. Trial results for lacosamide in painful diabetic neuropathy. Poster 
  41. Evaluation of Lacosamide in Diabetic neuropathic pain trials, page 21, The Journal of Pai , volume 9, number 4, supplement2 , April 2008
  42. EFNS (August 23-26, 2008; Madrid). (“Evaluation of lacosamide in diabetic neuropathic pain trials”) August 24, 2008, platform presentation
  43. 12th world congress ofn pain, Glasgow, Scotland, 17-22 August , 2008. . “Evaluation of lacosamide in diabetic neuropathic pain trials” poster
  44. CIDP: benefit from IVIG by patients who do not fit the criteria. Paris. Platform presentation.
  45. Evaluation of Lacosamide in Diabetic neuropathy Trials, 27th annual meeting of the APS, Tampa, Florida, May 8-10, 2008. Poster presentation
  46. Aziz Shaibani, et al; Evaluation of Lacosamide in Diabetic Neuropathic Trials, AAN 60th annual meeting, Chicago, April 12-19, 2008. Poster presentation 
  47. Aziz Shaibani, MD, et al Evaluation of Lacosamide in Diabetic neuropathic pain, Diabetic foot conference, LA, March 13-15, 2008.(poster) 
  48. Aziz Shaibani, MD et al Evaluation of Lacosamide in Diabetic Neuropathic Pain Trials. 24th Annual Meeting, American Academy of Pain Medicine, Orlando, Florida, February 2008. 
  49. Aziz Shaibani, MD, et al Lacosamide in Subjects with painful Distal Diabetic neuropathy: Results of a Multi-Center, Randomized, Double blind, Placebo controlled, Parallel-Group Trial. Poster. 11th Congress of the European Federation of neurological societies. Brussels, Belgium, August 25-28, 2007. 
  50. Randall Kaye, MD1; Ronald A. Thisted, PhD2; Adrian Hepner, MD1; Aziz Shaibani, MD, FACP Improved patient-centered outcomes with dextromethorphan/quinidine vs placebo in a Phase III, double-blind, randomized, placebo-controlled trial investigating painful diabetic peripheral neuropathy. Poster. Second international congress on neuropathic pain, Berlin , Germany, June 7-10, 2007.
  51. Aziz Shaibani, MD, FACP1; Ronald A. Thisted, PhD; Adrian Hepner, MD; Laura E. Pope, PhD; Randall Kaye, MD EFFICACY AND SAFETY OF DEXTROMETHORPHAN/QUINIDINE IN TREATING PAINFUL DIABETIC PERIPHERAL NEUROPATHY: RESULTS OF A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL . Poster. Second international congress on neuropathic pain, Berlin , Germany, June 7-10, 2007. 
  52. A. Shaibani, progressive loss of balance and generalized weakness. Journal of Clinical Neuromuscular Disease, volume 8, number 3, March 2007. 
  53. A. Shaibani. A multi-center, randomized, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of SPM 927 (200, 400, and 600 mg/day) in subjects with painful distal diabetic neuropathy, Aziz Shaibani for the SP768 Study Group, 19th World Diabetes Congress, 2006 Cape Town, South Africa. 
  54. A. Shaibani. A multi-center, randomized, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of SPM 927 (200, 400, and 600 mg/day) in subjects with painful distal diabetic neuropathy, Aziz Shaibani for the SP768 Study Group, session 774, APS 25th Annual Scientific meeting, 2006 San Antonio, Texas.  
  55. A. Shaibani. A multi-center, open-label trial to assess the safety and efficacy of Lacosamide in the Long-term treatment of diabetic neuropathic pain, Aziz Shaibani, P04.008, AAN 58th Annual Meeting 2006, San Diego, CA.  
  56. A. Shaibani, Houston, TX. The safety and efficacy of Lacosamide (SPM927) in the long term treatment of diabetic neuropathy pain. 8th International Conference on the Mechanisms and Treatment of Neuropathic Pain, San Francisco, November 2005. 
  57. A. Shaibani, Houston, TX. An open-label follow-on trial to assess the long-term safety and efficacy of oral Lacosamide (SPM927) in subjects with diabetic neuropathy. ID# 138761. 11th World Congress on Pain, August 2005, Sydney, Australia.  
  58. A. Shaibani, Houston, TX. Randomized, double-blind, placebo trial to investigate the safety and efficacy SPM927 in painful diabetic neuropathy. 56th annual meeting, AAN, May 2004, San Francisco.  
  59. Z. Elchami, A. Shaibani, Houston, TX. Three Patients with Numbness of the Feet. Journal of Child Neurology/volume 19, Number 3 March 2004.
  60. Z.F. Cheema, S. Khan, S. Shahkhan, N. Punay, Oklahoma City, OK; A Shaibani, Houston, TX. Hirayama’s Disease: Motor Neuron Disease or Subtle Cervical Cord Dysfunction? Journal of Child Neurology/volume 19, Number 3 March 2004.
  61. Shaibani A, Slowly Progressive extremities Weakness in an HIV-Positive Patient, Journal of Child Neurology/volume 19, Number 3 March 2004. 
  62. Shaibani A, Hall A. Giant cell polymyositis, Myasthenia gravis, And Thymoma, Journal of Child Neurology/volume15, Number3, March 2000. 
  63. Khan B, Khan A, Shaibani A. Focal Myositis, Journal of Child Neurology/volume15, Number3, March 2000.
  64. Khan A, Khan B, Shaibani A. Focal TB Myositis complicating Corticosteroid therapy for Dermatomyositis, Journal of Child Neurology/volume15, Number3, March 2000.
  65. Shaibani A, Harati Y, et al. Miyoshi myopathy with vacuoles. Poster, 49th meeting of the American Academy of Neurology, Boston, MA, April 1997. 
  66. Shaibani A., Harati Y., CTG repeat expansion is not the only determinant of pathology in myotonic dystrophy. ANA annual meeting, Miami, Florida, Nov. 1996. 
  67. Shaibani A, Harati Y. Lysosomal glycogenosis with high acid maltase activity, Abstract, Journal of child neurology, II, 2: 148-149, 1996. 
  68. Harati Y., Gooch C., Shaibani A. Moving toes and myoclonus associated with hereditary neuropathy with liability to pressure palsy (HNPP). Poster; Peripheral nerve society annual meeting, Antalya, Turkey, October 6-9, 1995.
  69. Pleitez M., Harati Y., Shaibani A., R.Harper, Foix-Alajounine presenting as peripheral neuropathy, poster, 47th Annual meeting of the American Academy of Neurology, May 6-13,1995.
  70. Harati Y., Shaibani A. IVIG and aseptic meningitis, “letters and corrections”, Annals of Internal Medicine, L94-537, Feb.15, 1995.
  71. Safi H, Iliopoulos DC, Gopinath SP, Hess KR, Asimacopoulos PJ, Bartoli S, Raskin SA, Shaibani A, Leveque M, and Yawn DH. Retrograde cerebral perfusion during profound hypothermia and circulatory arrest in pigs. Conference on CNS dysfunction after cardiac surgery: defining the problem, Fort Lauderdale, Florida, December 10-11, 1994